Dosage Forms. Lyophilized Powder for Subcutaneous Injection: 0.5 mL after reconstitution with supplied diluent; also available in combination with varicella vaccine
Common FDA Label Indication, Dosing, and Titration.
1. Prevention of measles, mumps, and rubella infections: Adults, one dose (second dose indicated for adults who are at high risk); Children, one dose at age 12 mo with a second dose at age 4-6 y, prior to entering school
Off-Label Uses. None
Drug Characteristics: Measles, Mumps, Rubella Vaccine, Live
Medication Safety Issues: Measles, Mumps, Rubella Vaccine, Live
Drug Interactions: Measles, Mumps, Rubella Vaccine, Live
Adverse Reactions: Measles, Mumps, Rubella Vaccine, Live
Efficacy Monitoring Parameters. Prevention of measles, mumps, and rubella infections; although antibody concentrations might be measured, routine measurement for vaccine response is not recommended.
Toxicity Monitoring Parameters. Syncope within 15 min of vaccine administration.
Key Patient Counseling Points. Some children may experience mild fever and rash 7-10 d after vaccine administration. Avoid pregnancy for 28 d following vaccine administration.
Clinical Pearls. Individuals born before 1957 can be considered immune unless a female of childbearing potential. Administer to females found to be seronegative to rubella following completion of pregnancy. If not administered simultaneously, MMR must be separated by at least 4 wk from other live vaccines. Individuals vaccinated between 1963 and 1967 with killed measles vaccine should be revaccinated. Individuals vaccinated before 1979 with inactivated mumps vaccine should be revaccinated. Avoid confusion with MMRV, which also contains varicella vaccine.